View Item 

Show simple item record

Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors

dc.contributor.authorOlszanski, Anthony J.
dc.contributor.authorSmith, David C.
dc.contributor.authorCamacho, Luis H.
dc.contributor.authorThompson, John
dc.contributor.authorRamalingam, Suresh S.
dc.contributor.authorHarvey, R. Donald
dc.contributor.authorCampos, Luis
dc.contributor.authorFerry, David
dc.contributor.authorTang, Shande
dc.contributor.authorGao, Ling
dc.contributor.authorSafran, Howard
dc.date.accessioned2017-12-15T16:46:43Z
dc.date.available2017-12-15T16:46:43Z
dc.date.issued2016-04
dc.identifier.citationOlszanski, Anthony J.; Smith, David C.; Camacho, Luis H.; Thompson, John; Ramalingam, Suresh S.; Harvey, R. Donald; Campos, Luis; Ferry, David; Tang, Shande; Gao, Ling; Safran, Howard (2016). "Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors." The Oncologist 21(4): 402-403f.
dc.identifier.issn1083-7159
dc.identifier.issn1549-490X
dc.identifier.urihttps://hdl.handle.net/2027.42/139908
dc.publisherAlphaMed Press
dc.publisherWiley Periodicals, Inc.
dc.titleElectrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelHematology and Oncology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.contributor.affiliationumUniversity of Michigan, Ann Arbor, Michigan, USA
dc.contributor.affiliationotherEli Lilly and Company, Bridgewater, New Jersey, USA
dc.contributor.affiliationotherFox Chase Cancer Center, Philadelphia, Pennsylvania, USA
dc.contributor.affiliationotherCenter for Oncology and Blood Disorders, Houston, Texas, USA
dc.contributor.affiliationotherSeattle Cancer Care Alliance, Seattle, Washington, USA
dc.contributor.affiliationotherWinship Cancer Institute of Emory University, Atlanta, Georgia, USA
dc.contributor.affiliationotherOncology Consultants, Houston, Texas, USA
dc.contributor.affiliationotherRhode Island Hospital, Providence, Rhode Island, USA
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/139908/1/onco0402.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/139908/2/onco0402-sup-0001.pdf
dc.identifier.doi10.1634/theoncologist.2015-0467
dc.identifier.sourceThe Oncologist
dc.identifier.citedreferenceEG Chiorean, HI Hurwitz, RB Cohen. Phase I study of every 2‐ or 3‐week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor‐2 in patients with advanced solid tumors. Ann Oncol. 2015; 26: 1230 – 1237.
dc.identifier.citedreferenceU.S. Department of Health and Human Services. Guidance for industry: E14: clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non‐antiarrhythmic drugs. Available at http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073153.pdf. Accessed September 22, 2015
dc.identifier.citedreferenceJL Spratlin, RB Cohen, M Eadens. Phase I pharmacologic and biologic study of ramucirumab (IMC‐1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor‐2. J Clin Oncol. 2010; 28: 780 – 787.
dc.identifier.citedreferenceCL Bello, M Mulay, X Huang. Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: Pharmacokinetic‐pharmacodynamic evaluation of sunitinib. Clin Cancer Res. 2009; 15: 7045 – 7052.
dc.identifier.citedreferenceY Liu, Y Liu, ZW Fan. Meta‐analysis of the risks of hypertension and QTc prolongation in patients with advanced non‐small cell lung cancer who were receiving vandetanib. Eur J Clin Pharmacol. 2015; 71: 541 – 547.
dc.identifier.citedreferenceJ Tabernero, T Yoshino, AL Cohn. Ramucirumab versus placebo in combination with second‐line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first‐line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double‐blind, multicentre, phase 3 study [published correction appears in Lancet Oncol 2015;16:e262]. Lancet Oncol. 2015; 16: 499 – 508.
dc.identifier.citedreferenceEB Garon, TE Ciuleanu, O Arrieta. Ramucirumab plus docetaxel versus placebo plus docetaxel for second‐line treatment of stage IV non‐small‐cell lung cancer after disease progression on platinum‐based therapy (REVEL): A multicentre, double‐blind, randomised phase 3 trial. Lancet. 2014; 384: 665 – 673.
dc.identifier.citedreferenceH Wilke, K Muro, E Van Cutsem. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro‐oesophageal junction adenocarcinoma (RAINBOW): A double‐blind, randomised phase 3 trial. Lancet Oncol. 2014; 15: 1224 – 1235.
dc.identifier.citedreferenceU.S. Department of Health and Human Services. National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. Available at http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40. Accessed February 21, 2016
dc.identifier.citedreferenceCS Fuchs, J Tomasek, CJ Yong. Ramucirumab monotherapy for previously treated advanced gastric or gastro‐oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo‐controlled, phase 3 trial. Lancet. 2014; 383: 31 – 39.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
onco0402.pdf
Size:
860.3KB
Format:
PDF
View/Open
Name:
onco0402-sup-0001.pdf
Size:
1.599MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.